Grifols details Value Creation Plan at CMD

The Value Creation Plan presented at Capital Markets Day, CMD, is based on 3 pillars: Commercial Growth: Grifols (GRFS) plans to capitalize on increasing demand for immunoglobulins and expand its product offerings in untapped markets to better serve its patient base. Margin Expansion: To further enhance profitability, Grifols will optimize its plasma sourcing mix, improve donor center performance and drive yield improvements across its plasma collection and manufacturing networks. Pipeline Execution: In the coming years Grifols is committed to delivering innovative new products, including the highly anticipated fibrinogen therapy, which is expected to launch in the EU in the second half of 2025 and in the U.S. in early 2026. Other key products, such as trimodulin, will further strengthen the company’s portfolio, alongside ongoing investments in R&D for future therapeutics.